Cancer is a global health challenge where early detection is critical for better patient outcomes. Traditional cancer detection techniques, such as imaging and biopsy, often diagnose the disease at advanced stages, reducing the chances of successful treatment. Against this backdrop, new partnerships in Singapore are facilitating access to innovative early-stage cancer detection methods, leveraging advanced technologies like next-generation sequencing (NGS), according to GlobalData.
Kanchan Chauhan, Medical Devices Analyst at GlobalData, states, “Collaborations with domestic and international organisations, integrating advanced technologies such as NGS into cancer detection, are essential to meet the urgent need for early-stage detection methods. These partnerships enable the identification of cancer in its initial stages, facilitating timely interventions that greatly enhance prognosis and survival rates.”
Singapore has recently embarked on a significant collaboration with Thermo Fisher Scientific, the National University Hospital, Singapore, and MiRXES. This partnership seeks to advance cancer detection testing by genomic solutions tailored to the Southeast Asian population. The new, user-friendly testing solutions use NGS for detailed genetic analysis and cancer research to predict cancer progression and suggest personalised treatment plans, ensuring therapies are precisely suited to individual genetic profiles and increasing the likelihood of successful treatment.
“With its visionary approach to cancer detection, Singapore marks a bold stride in healthcare innovation through strategic collaboration. Leading with pioneering technologies, the nation sets a new standard in global healthcare, inspiring a future where precision medicine revolutionises patient care worldwide,” concludes Chauhan .